U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2013
596
Substance Class Protein
Created
by admin
on Sat Dec 16 16:30:40 GMT 2023
Edited
by admin
on Sat Dec 16 16:30:40 GMT 2023
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG1
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
O43472U9X8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OBINUTUZUMAB
DASH   INN   MART.   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
OBINUTUZUMAB [MI]
Common Name English
AFUTUZUMAB
Common Name English
RO5072759
Code English
OBINUTUZUMAB [MART.]
Common Name English
HUMABCD20
Common Name English
OBINUTUZUMAB [USAN]
Common Name English
RG-7159
Code English
IMMUNOGLOBULIN G1, ANTI-(HUMAN CD20 (ANTIGEN)) (HUMAN-MOUSE MONOCLONAL GA101 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL GA101 .KAPPA.-CHAIN, DIMER
Common Name English
RO-5072759 HUMAB CD20
Code English
OBINUTUZUMAB [JAN]
Common Name English
OBINUTUZUMAB [VANDF]
Common Name English
GAZYVA
Brand Name English
OBINUTUZUMAB [PURPLE BOOK CDER]
Common Name English
Obinutuzumab [WHO-DD]
Common Name English
GA101
Code English
obinutuzumab [INN]
Common Name English
RO-5072759
Code English
IMMUNOGLOBULIN G1, ANTI-(HUMAN CD20 (ANTIGEN)) (HUMAN-MOUSE MONOCLONAL GA101 HEAVY CHAIN), DISULPHIDE WITH HUMAN-MOUSE MONOCLONAL GA101 .KAPPA.-CHAIN, DIMER
Common Name English
HUMAB CD20
Code English
GAZYVARO
Brand Name English
GA-101
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 473315
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
WHO-ATC L01XC15
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
EU-Orphan Drug EU/3/14/1325
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
FDA ORPHAN DRUG 727719
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
FDA ORPHAN DRUG 889422
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
NCI_THESAURUS C129822
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
NCI_THESAURUS C141215
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
FDA ORPHAN DRUG 824921
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
NDF-RT N0000175657
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
FDA ORPHAN DRUG 592717
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
FDA ORPHAN DRUG 473415
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
FDA ORPHAN DRUG 360011
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
EMA ASSESSMENT REPORTS GAZYVARO (AUTHORIZED: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL)
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
FDA ORPHAN DRUG 359911
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
WHO-VATC QL01XC15
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
Code System Code Type Description
RXCUI
974779
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
PRIMARY RxNorm
MERCK INDEX
m11722
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
PRIMARY
SMS_ID
100000125968
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
PRIMARY
DRUG BANK
DB08935
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
PRIMARY
HSDB
8249
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
PRIMARY
IUPHAR
6941
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
PRIMARY
NCI_THESAURUS
C70741
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
PRIMARY
DRUG CENTRAL
4983
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
PRIMARY
USAN
UU-119
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
PRIMARY
FDA UNII
O43472U9X8
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
PRIMARY
WIKIPEDIA
OBINUTUZUMAB
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
PRIMARY
LACTMED
Obinutuzumab
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
PRIMARY
INN
9043
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
PRIMARY
EVMPD
SUB32751
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
PRIMARY
ChEMBL
CHEMBL1743048
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
PRIMARY
CAS
949142-50-1
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
PRIMARY
DAILYMED
O43472U9X8
Created by admin on Sat Dec 16 16:30:40 GMT 2023 , Edited by admin on Sat Dec 16 16:30:40 GMT 2023
PRIMARY
From To
1_22 1_96
1_146 1_202
1_222 3_219
1_228 2_228
1_231 2_231
1_263 1_323
1_369 1_427
2_22 2_96
2_146 2_202
2_222 4_219
2_263 2_323
2_369 2_427
3_23 3_93
3_139 3_199
4_23 4_93
4_139 4_199
Related Record Type Details
B-LYMPHOCYTE ANTIGEN CD20
TARGET->LIGAND
B-LYMPHOCYTE ANTIGEN CD20
TARGET -> INHIBITOR
Related Record Type Details
OBINUTUZUMAB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
MOL_WEIGHT:SEQUENCE CHEMICAL
Molecular Formula CHEMICAL
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966